Three-year follow-up data show that nemolizumab sustains clinically meaningful responses in adults with moderate-to-severe atopic dermatitis, according to commentary from Matthias Augustin, MD, featured in HCPLive.

The long-term extension findings, which track patients out to 36 months of continuous therapy, address one of the central questions in chronic AD management: whether the rapid itch and skin clearance seen in the pivotal trials translate into durable disease control.

What does a 3-year signal change?

Atopic dermatitis is a relapsing, year-round disease for most adults who escalate to systemic therapy. Loss of efficacy between 12 and 24 months has historically forced switches between agents, particularly within older immunosuppressive classes such as cyclosporine and methotrexate. A consistent three-year response curve shifts the calculus for both clinicians and payers, who weigh acquisition cost against durable remission.

Matthias Augustin, MD, presented the long-term perspective to HCPLive. A leading European atopic dermatitis outcomes researcher, Augustin argued that durability, not just week-16 endpoints, should drive formulary decisions in chronic AD.

Where does nemolizumab sit in the systemic AD armamentarium?

Nemolizumab is a monoclonal antibody directed against the IL-31 receptor A. IL-31 is the cytokine most strongly linked to pruritus in atopic dermatitis, and blocking its receptor decouples the itch-scratch cycle that drives much of the disease's morbidity.

The agent received FDA approval in 2024 for adults and pediatric patients aged 12 and older with moderate-to-severe disease whose symptoms are not adequately controlled with topical prescription therapies. Approval rested on the ARCADIA 1 and ARCADIA 2 pivotal trials, which demonstrated significant improvements in Eczema Area and Severity Index (EASI) scores and patient-reported pruritus at week 16.

The 3-year extension data extend that profile. They move the discussion from "does it work at week 16" to "does it keep working when the patient still has the disease five winters from now."

Why does itch control matter clinically?

The pruritus endpoint has become a primary differentiator across the systemic AD class. Dupilumab, the first IL-4/IL-13 inhibitor approved for atopic dermatitis, established the modern template, but anti-IL-31 mechanisms appear to deliver particularly rapid itch relief, often within the first week of dosing.

Augustin framed itch as the symptom patients describe as most burdensome, and tied the speed of relief directly to long-term adherence.

What remains unresolved?

Head-to-head comparisons against dupilumab and the newer Janus kinase (JAK) inhibitors are limited. Long-term safety at three years will continue to accrue, particularly with respect to any signals of conjunctivitis, which has been a recurring class consideration for IL-pathway agents.

The reimbursement and access picture across the United States and Europe also continues to evolve. Step-therapy requirements vary by payer, by country, and increasingly by prior biologic exposure.

What does this mean for practice?

The 3-year dataset positions nemolizumab as a maintenance option in moderate-to-severe AD, with pruritus control as a clinically meaningful differentiator. As longer-term real-world evidence accumulates, the conversation shifts toward sequencing decisions and combination strategies in patients who cycle through multiple systemic agents over a lifetime of disease.